TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00615745
Drug: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
Study: NCT03055247
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
Study: NCT03055247
Drug: Myelostim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
Study: NCT04129164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose matched to VIB4920.
Study: NCT00002870
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002870
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03215940
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
Study: NCT03950700
Drug: Bupivacaine-epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S
Study: NCT01131559
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; 20-70mg/day
Study: NCT05761418
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: prostaglandin (PG) E2 analog
Study: NCT02214940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00696943
Drug: ([18F]-ML-10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of \[18F\]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
Study: NCT00305227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04361799
Drug: Standard insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin therapy according to local clinical practice.
Study: NCT01781104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered subcutaneously once daily for 14 days.
Study: NCT02672852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for risankizumab administered by subcutaneous injection
Study: NCT01923428
Drug: AZD1722
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00206427
Drug: GW572016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib, 500 mg
Study: NCT01923428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01151306
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20mg once daily (in the evening) for 6 weeks
Study: NCT01151306
Drug: Lactose tablet
Normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet taken each evening for 6 weeks
Study: NCT01704755
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
Study: NCT00938353
Drug: Placebo solution for nebulisation 2 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose: 4 ml
Study: NCT00281697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00281697
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle.
Study: NCT00113295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02553824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
Study: NCT01779570
Drug: Macrolide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02299440
Drug: 1st perfusion of saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
Study: NCT02299440
Drug: 2nd perfusion of saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
Study: NCT03312842
Drug: CS1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type.
Study: NCT02666989
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo pills twice a day
Study: NCT02683239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive sub-cutaneous (SC) injections of matching placebo
Study: NCT00202020
Drug: Aspirin 100mg/day Oral
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03350490
Drug: Life information rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT02104245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02454348
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
Study: NCT03165747
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
Study: NCT03221998
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 gram paracetamol infusion for moderate pain management
Study: NCT02005575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03231800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily
Study: NCT00504673
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003187
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003187
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02137889
Drug: VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
Study: NCT00768170
Drug: MK0633
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0633 (50 mg) Oral, single dose
Study: NCT00951015
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational HIV-1 integrase inhibitor
Study: NCT04644120
Drug: Placebo for ABBV-47D11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion.
Study: NCT04644120
Drug: Placebo for ABBV-2B04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervenous (IV) Infusion
Study: NCT02188654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day of placebo tablets
Study: NCT00137969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as a sterile liquid for IV administration.
Study: NCT00137969
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01416389
Drug: LY2523355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously as a one hour infusion
Study: NCT04406506
Drug: (erythromycin 250 mg IV bolus)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
Study: NCT02488382
Drug: Lonquek
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
Study: NCT02950935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
Study: NCT00671996
Drug: Placebo treatment (0.9% NaCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
Study: NCT03873246
Drug: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
Study: NCT00932542
Drug: Eutectic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eutectic mixture of lidocaine + prilocaine + bupivacaine.
Study: NCT00932542
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02536820
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual diabetes treatment in each participant
Study: NCT03586908
Drug: PHP-201 0.5% ophthalmic solution (topical eye drop)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2\~D6: PHP-201 0.5% topical eye drop OU TID
Study: NCT04240223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00632489
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
Study: NCT00632489
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
Study: NCT00452777
Drug: BVT.115959
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00452777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03878277
Drug: Starbucks® Cold brew - 325ml bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
Study: NCT00777868
Drug: Low Strength IDP-108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application once a day for 9 months
Study: NCT00777868
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application once a day for 9 months
Study: NCT04293809
Drug: Exparel Injectable Product
Normalized name: Exparel Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine liposome injectable suspension
Study: NCT03208309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03227484
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily over 8 weeks
Study: NCT01081782
Drug: ONO-4641 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once per day for 26 weeks
Study: NCT03297424
Drug: PLX2853
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00469690
Drug: Acular, Xibrom
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~2. Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)
Study: NCT00573859
Drug: ADHD medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
Study: NCT00573859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the placebo condition, participants received placebo pills for two consecutive days.
Study: NCT02260089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01432587
Drug: Diflunisal
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
Study: NCT01559129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules taken orally once a day
Study: NCT01986764
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01986764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be filled with lactose powder.
Study: NCT00647933
Drug: Lyndiol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
Study: NCT02623582
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04671966
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand name Climara for estrogen add back portion of study. Premenopausal women treated with a GnRH antagonist will be randomized to estrogen add-back or placebo. Thus, for women without contradictions to estrogen use, the risks associated with their use for the duration proposed in these studies (i.e., 6 days) are small. The respective estradiol regimen is a standard approved dose for treatment of hot flashes and the prevention of osteoporosis, and this dose will increase E2 to concentrations typically observed during the mid to late follicular phase of the menstrual cycle.
Study: NCT02535091
Drug: YKP3089
Approvals — FDA: no, EMA: no, PMDA: no
Description: see above
Study: NCT05319912
Drug: ALXN1840 Non-coated Capsule
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
Study: NCT03101839
Drug: AZD4785
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRAS Antisense Oligonucleotide
Study: NCT03750786
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion
Study: NCT01349660
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 orally (PO) once daily
Study: NCT00939562
Drug: doxycycline carragenate tablet
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, 100 mg, Single dose
Study: NCT05236907
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
Study: NCT00612560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill 1 per day
Study: NCT00506441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
Study: NCT02104778
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
Study: NCT00684723
Drug: Lovastatin 40 mg Tablets
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
Study: NCT00684723
Drug: Lovastatin (Mevacor®) 40 mg Tablets
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
Study: NCT04276415
Drug: DS-6157a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single agent intravenously (IV) every 3 weeks
Study: NCT04088318
Drug: OQL011
Approvals — FDA: no, EMA: no, PMDA: no
Description: OQL011 is an ointment containing active ingredient.
Study: NCT00338793
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01815736
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study: NCT01815736
Drug: E/C/F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Study: NCT01815736
Drug: EFV/FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/200/300 mg FDC tablet administered orally once daily
Study: NCT01815736
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet administered orally once daily
Study: NCT00222872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
Study: NCT00242411
Drug: Conventional Best Asthma Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01815736
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/300 mg tablet administered orally once daily
Study: NCT02729064
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
Study: NCT01905150
Drug: G-FLIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
Study: NCT01602029
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
Study: NCT01602029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to TAU
Study: NCT01602029
Drug: Odansetron plus simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
Study: NCT02114619
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will administer 150 micro currie of iodine per thyroid gram
Study: NCT02114619
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will administer 200 micro currie of iodine per thyroid gram
Study: NCT02085395
Drug: SR-T100 ® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01737307
Drug: CPP-ACP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPP-ACP paste was applied by patient, once daily.
Study: NCT04413344
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Identical tablets which contain no active ingredient
Study: NCT00019461
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01209234
Drug: MRSA Decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
Study: NCT00646399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
Study: NCT02431312
Drug: Nucleos(t)ide Analogue Treatment
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with nucleos(t)ide analogue
Study: NCT02314481
Drug: MPDL3280A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
Study: NCT04069221
Drug: Single oral dose of 800 mg OZ439
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 800 mg OZ439